Supernus Pharmaceuticals Inc.’s (SUPN) share price has entered into oversold territory with an RSI value of 27.1. The Zacks Consensus Estimate on Supernus Pharmaceuticals Inc.’s earnings for the full year period has loss of 0.01 cents over the past two months to $-2.49 per share. Currently, Supernus Pharmaceuticals Inc. is a Zacks #2 Rank (“Buy”), suggesting that now might be a good time to get in on (SUPN) after its recent drop.
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment